DEA June 29 Hearing Explained: What's at Stake for Adult-Use Cannabis

The Justice Department's April 23 order placing FDA-approved and state-licensed medical marijuana into Schedule III was the headline-grabbing move. The hearing that begins on June 29, 2026 is the one that could actually finish the job. That proceeding, scheduled to wrap "no later than July 15," is where the DEA will weigh whether the rest of the cannabis market — adult-use programs in 24 states — gets pulled out of Schedule I along with medical.

For operators waiting on full 280E relief, banking access, and an end to the legal contortions of working in a federally illegal industry, the next 60 days matter more than the headlines suggest.

What the June 29 hearing is — and isn't

The April 23 order did two things at once. First, it immediately moved a narrow slice of cannabis — FDA-approved drug products and products produced under a "qualifying state-issued medical license" — into Schedule III, the same category as ketamine and Tylenol with codeine. Second, it directed the DEA to schedule a new administrative hearing to evaluate broader rescheduling of all marijuana under the Controlled Substances Act.

That hearing is what kicks off June 29 and runs through July 15, 2026.

The proceeding picks up where the previous DEA rescheduling process stalled in early 2025. According to the DOJ's official notice and law-firm analyses from Foley & Lardner, Vicente LLP, Duane Morris, and Foley Hoag, the June 29 hearing will "receive factual evidence and expert opinion regarding" whether marijuana — broadly, not just medical — should be transferred to Schedule III.

In practical terms, the hearing is the formal record-building exercise required by the Administrative Procedure Act before DEA can finalize a broader rescheduling rule. Witnesses, briefs, and exhibits filed during the hearing become the evidentiary basis for any subsequent final rule. Without it, a broader rescheduling rule would be vulnerable to immediate court challenge for procedural failure.

The May 24 deadline almost no one is talking about

The most consequential date in the calendar isn't June 29. It's May 24, 2026 at 11:59 p.m. ET — the deadline for any party that wants to participate in the hearing to file a notice of intention.

The Federal Register notice governing the proceeding will lock in the participant list on that date and set the schedule for pre-hearing briefing and evidence submission. That participant list determines who gets to put a witness on the stand, cross-examine the government's experts, and submit written testimony into the formal record. Industry groups, state regulators, anti-rescheduling organizations like Smart Approaches to Marijuana, medical associations, and individual operators all have to file by May 24 or watch from the sidelines.

The previous DEA process drew dozens of designated participants — and a series of motions, scheduling fights, and recusal disputes that pushed the final hearing date back by more than a year. The compressed June 29-to-July 15 window in this round suggests the DEA is trying to short-circuit that pattern, but participation decisions made before May 24 will set the tone.

What broader rescheduling would actually change

If the June 29 hearing produces a record sufficient for the DEA to finalize a Schedule III rule for all marijuana, the downstream effects would be larger than the medical-only April 23 order delivered.

Tax relief expands to adult-use operators. The IRS Section 280E penalty — which prevents Schedule I and II businesses from deducting normal operating expenses — applies to every cannabis retailer, cultivator, and manufacturer in every adult-use state today. Effective tax rates run as high as 70 percent of net income for some operators. Schedule III removes the 280E penalty entirely. AdvisorShares, which manages the largest U.S. cannabis ETF, projects effective tax rates falling from roughly 56 percent to about 21 percent for the multi-state operators in its portfolio if broader rescheduling lands.

Research access opens up. Schedule III drugs can be studied at any DEA-registered research site without the special Schedule I registration that has bottlenecked U.S. cannabis science for 50 years. Universities, hospitals, and pharma companies that have stayed out of cannabis research because of administrative friction would have a much shorter on-ramp.

Banking and capital markets shift, slowly. Rescheduling alone does not legalize marijuana for federal purposes. The plant remains a controlled substance, and federal banking regulators will still require institutions to follow anti-money-laundering rules tied to controlled substances. But Schedule III status removes one of the cleanest reasons banks have given for refusing accounts. Combined with potential SAFER Banking Act movement, the practical access to depository services, payment processing, and institutional capital should ease over the months that follow a final rule.

Interstate commerce remains illegal. Cannabis crossing state lines is still a federal offense regardless of schedule. The patchwork of state-licensed markets stays a patchwork.

What the hearing won't decide

A few things the June 29 hearing is not going to do, despite the headlines that will inevitably suggest otherwise:

• It won't legalize recreational marijuana. Schedule III is a controlled-substance classification, not a legalization status. Adult-use markets remain federally unlawful even if the rule lands.
• It won't finalize a rule on the spot. The hearing builds a record. A subsequent agency rulemaking, with notice-and-comment, would still be required to issue a final rule covering all marijuana.
• It won't preempt state enforcement decisions. States that have refused to legalize, or that are pursuing rollback initiatives, retain full authority over marijuana under state law.
• It won't immediately resolve the Bill Barr lawsuit. Smart Approaches to Marijuana's planned legal challenge to the April 23 order is a separate track. The June 29 hearing record could end up being cited in that litigation, but the cases run in parallel.

The political backdrop

The April 23 reschedule and the June 29 hearing are both happening under an administration that, as of late 2025, was widely expected to slow-walk cannabis reform. The Trump administration's pivot — driven by acting Attorney General Todd Blanche's April 22 order and a presidential endorsement of medical marijuana — caught most policy observers off guard.

The hearing's compressed timeline reflects that political momentum. The DEA is explicitly trying to move faster than the previous process, which spent more than 18 months in pre-hearing motions before collapsing on procedural grounds in early 2025. That speed cuts both ways: it forces opponents to mobilize quickly, but it also limits the depth of the evidentiary record industry advocates can build.

Smart Approaches to Marijuana's hire of former Attorney General Bill Barr to litigate against the April 23 order signals that the opposition is gearing up. Expect SAM, several state attorneys general, and at least one law-enforcement coalition to file as participants before the May 24 deadline.

What operators should do now

For licensed cannabis operators — cultivators, manufacturers, retailers, lab testers, and ancillary services — the next 60 days are decision time on three fronts:

1. Decide whether to participate. Filing as a designated participant means committing legal resources to briefs, witnesses, and cross-examination. It also means a seat at the table. Trade associations like the U.S. Cannabis Council, the National Cannabis Industry Association, and Marijuana Policy Project are coordinating multi-operator filings to spread the cost.

2. Document the case for adult-use rescheduling. The hearing record is where evidence on safety, public health outcomes from legalized states, tax revenue impacts, and operator economics gets formally entered. Operators sitting on internal data — adverse-event reports, patient surveys, employment numbers — should be ready to share it through trade associations or directly.

3. Plan for two scenarios. A final rule that covers all marijuana would expand the April 23 medical-only relief to roughly 24 adult-use states and an estimated $32 billion in legal sales. A final rule limited to medical, or one that gets tied up in litigation, leaves adult-use operators in the same 280E penalty box they're in today. Operating models should be stress-tested against both outcomes.

Timeline at a glance

• April 22, 2026 — Acting AG Todd Blanche issues the order rescheduling FDA-approved and state-licensed medical marijuana to Schedule III; directs DEA to schedule a broader hearing.
• April 23, 2026 — DEA publishes the order; medical marijuana relief takes effect immediately for qualifying operators.
• May 24, 2026, 11:59 p.m. ET — Deadline for parties to file a notice of intention to participate in the broader rescheduling hearing.
• June 29, 2026 — DEA administrative hearing on rescheduling all marijuana to Schedule III begins.
• July 15, 2026 — Hearing must conclude no later than this date.
• TBD — DEA issues a proposed rule, opens public comment, and ultimately issues a final rule covering broader rescheduling. No statutory deadline.

Key Takeaways

• The June 29, 2026 DEA hearing is the procedural step that could extend Schedule III to all marijuana, including adult-use markets.
• The May 24 deadline to file a notice of intention to participate is the most important near-term date for industry, advocacy groups, and opponents.
• Broader rescheduling would deliver 280E tax relief to roughly 24 adult-use states, expand U.S. cannabis research access, and ease banking access — but it does not legalize marijuana federally.
• The hearing builds the evidentiary record. A separate notice-and-comment rulemaking would still be required to finalize broader rescheduling.
• The compressed June 29 to July 15 window reflects the Trump administration's push to avoid the 18-month delays that derailed the previous rescheduling process.

Related Schedule III Coverage

• DOJ signs the Schedule III order — what it actually does
• End of 280E: how operators capture the tax savings
• Bill Barr's SAM lawsuit threatens to delay it all

Tracking every step of cannabis rescheduling? Search a dispensary near me on Budpedia to see what's already stocked across the 38 legal states while the DEA hearing plays out.